Ascendis Pharma A/S (ASND) is up 8.8% today. Here is some analysis on what might have caused this price movement.
Analysis: The move does not appear tied to one fresh headline, so the most likely explanation is a mix of fundamental and technical drivers. This could be because investors are responding to the company’s new cash from its priority review voucher sale, recent positive endocrine and achondroplasia data, and possible buying ahead of its expected Russell 1000 inclusion.
Details:
Ascendis disclosed on June 17, 2026 that it completed the sale of its rare pediatric disease priority review voucher for $187.5 million in cash, adding a meaningful non-dilutive funding source.Recent June presentations highlighted long-term TransCon PTH results in hypoparathyroidism with sustained efficacy and safety, plus two-year pivotal data for TransCon CNP showing strong growth outcomes in children with achondroplasia aged 5 and older.In first-quarter 2026 results, the company reported €247 million in revenue, non-IFRS net profit of €18 million, and €573 million in cash before the later voucher-sale proceeds.FTSE Russell’s June 2026 reconstitution materials listed Ascendis Pharma as a new Russell 1000 addition, which can create short-term demand from index-linked and event-driven investors as the effective date approaches.Sources:
Ascendis Pharma, SEC, LSEG
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ASND Insider Trading Activity
$ASND insiders have traded $ASND stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ASND stock by insiders over the last 6 months:
- JEAN JACQUES BIENAIME has made 5 purchases buying 900 shares for an estimated $206,682 and 0 sales.
- SCOTT THOMAS SMITH (EVP & Chief Financial Officer) has made 2 purchases buying 350 shares for an estimated $77,730 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EARLY ACCESS
Receive ASND Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$ASND Hedge Fund Activity
We have seen 144 institutional investors add shares of $ASND stock to their portfolio, and 191 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,586,394 shares (-59.5%) from their portfolio in Q4 2025, for an estimated $338,282,656
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,570,260 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $359,165,569
- CAPITAL INTERNATIONAL INVESTORS removed 1,105,100 shares (-36.1%) from their portfolio in Q1 2026, for an estimated $252,769,523
- CAPITAL WORLD INVESTORS added 900,517 shares (+inf%) to their portfolio in Q1 2026, for an estimated $205,975,253
- CITADEL ADVISORS LLC removed 519,516 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $118,828,894
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 442,889 shares (-94.0%) from their portfolio in Q1 2026, for an estimated $101,302,000
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 372,256 shares (-7.2%) from their portfolio in Q1 2026, for an estimated $85,146,114
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ASND Analyst Ratings
Wall Street analysts have issued reports on $ASND in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 01/30/2026
To track analyst ratings and price targets for $ASND, check out Quiver Quantitative's $ASND forecast page.
$ASND Price Targets
Multiple analysts have issued price targets for $ASND recently. We have seen 10 analysts offer price targets for $ASND in the last 6 months, with a median target of $308.5.
Here are some recent targets:
- Eric Joseph from Citigroup set a target price of $355.0 on 05/19/2026
- Josh Schimmer from Evercore ISI Group set a target price of $329.0 on 05/15/2026
- Eliana Merle from Barclays set a target price of $345.0 on 05/11/2026
- Derek Archila from Wells Fargo set a target price of $326.0 on 05/08/2026
- Tazeen Ahmad from B of A Securities set a target price of $292.0 on 04/16/2026
- Yun Zhong from Wedbush set a target price of $273.0 on 04/09/2026
- Kelly Shi from Jefferies set a target price of $290.0 on 03/16/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Ascendis Pharma jumps as investors weigh cash boost, pipeline momentum, and possible index-related buying
Ascendis Pharma A/S (ASND) is up 8.8% today. Here is some analysis on what might have caused this price movement.
Analysis: The move does not appear tied to one fresh headline, so the most likely explanation is a mix of fundamental and technical drivers. This could be because investors are responding to the company’s new cash from its priority review voucher sale, recent positive endocrine and achondroplasia data, and possible buying ahead of its expected Russell 1000 inclusion.
Details:
Sources:
Ascendis Pharma, SEC, LSEG
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ASND Insider Trading Activity
$ASND insiders have traded $ASND stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ASND stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ASND Hedge Fund Activity
We have seen 144 institutional investors add shares of $ASND stock to their portfolio, and 191 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ASND Analyst Ratings
Wall Street analysts have issued reports on $ASND in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $ASND, check out Quiver Quantitative's $ASND forecast page.
$ASND Price Targets
Multiple analysts have issued price targets for $ASND recently. We have seen 10 analysts offer price targets for $ASND in the last 6 months, with a median target of $308.5.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »